CSE: PREV WELCOME OTCQB: PRVCF
CSE: PREV WHO WE ARE OTCQB: PRVCF Head quartered in Vancouver, British Columbia, PreveCeutical Medical Inc. is a preventive health sciences company that develops leading-edge options for curative and preventive therapies. The company is led by an experienced team of senior executives and scientists with a passion for researching and developing innovative solutions for unmet clinical needs. The company is staking out important positions in diverse areas such as diabetes and obesity, pain management, neurological disorders and cancer and building an innovative IP portfolio for licensing and strategic partnerships. PreveCeutical believes the medical community is transitioning from a system that often only manages symptoms to one of personalized, preventive-based treatments. With this focus, PreveCeutical is committed to becoming a leader in preventive health sciences.
CSE: PREV WHO WE ARE OTCQB: PRVCF MISSION STATEMENT To improve global health and healthcare by utilizing innovative science and cutting-edge technology to enhance natural products. VISION To be a trusted leader in providing preventive and therapeutic health solutions that contribute to lasting health and well-being. PHILOSOPHY • Conduct business with honesty and integrity in an innovative and open environment. • Model high-quality governance, leadership and management • Make available the best and trusted health and wellness solutions.
CSE: PREV RECENT ACHIEVEMENTS OTCQB: PRVCF Our cannabinoid-based Sol-gel program approval for the use of human tissue in the final phase, unique in pre-clinical development – likely to lead to fast-tracking through to clinical trials allowing us to work on proof of concept. Positive developments in our Diabetes and Obesity ‘Dual Gene Program.’ Our research team has finalized 4 (possibly more) highly potent, and novel, Silencing RNA (siRNA) candidates each of which silence the target gene and protein in mice AND human-derived cells by more than 80%. The unique sequences of siRNA are PreveCeutical’s IP.
CSE: PREV CURRENT PROGRAMS OTCQB: PRVCF PreveCeutical has partnered with the University of Queensland for research and development. Agreements in place give PreveCeutical ownership over program outcomes - IP and results. Sol-gel platform for nose-to-brain delivery of medical cannabinoids. Nature Identical ™ (synthetic) peptides to assist with treatment of aggressive (brain) cancers and a range of ailments. Non-addictive, analgesic peptides to substitute dependence- associated opioids. Dual gene therapy for the treatment/prevention of type 2 diabetes and obesity.
CSE: PREV DEVELOPMENT PIPLINE OTCQB: PRVCF IND Opportunity Lead Pre-clinical Development Pipeline Clinical Trials Discovery Registration Analysis Optimization Studies Ph. II Ph. IIa Ph. IIb Ph. III POC Sol-gel Complete Out-license/partner ongoing Nature Identical™ Out-license/partner Complete ongoing Non-addictive Analgesics Complete Out-license/partner ongoing Dual Gene Therapy Complete Out-license/partner ongoing • PreveCeutical has the use of UQ’s Linker Technology, which enables us to stabilize peptides as we are making them! Effectively one-pot synthesis – does not require post synthesizing modalities. Faster and less labour intensive.
CSE: PREV SOL-GEL OTCQB: PRVCF
CSE: PREV SOL-GEL OTCQB: PRVCF Developing the first, sustained-release, Cannabis and CBD-based, nose-to-brain delivery system that will provide relief across a range of indications from pain, seizures, and neurological disorders. ▪ Proprietary formulation - delivery via a custom nasal spray device. ▪ Bypasses first pass metabolism - dramatically increasing bioavailability, even compared to conventional delivery mechanisms. ▪ Universally-patient friendly, water soluble, alcohol free safe for use in adults, children and people with alcohol-based restrictions.
CSE: PREV SOL-GEL OTCQB: PRVCF PreveCeutical’s research team at the University of Queensland has been granted the necessary approvals from a local hospital’s Human Ethics Committee for the use of human nasal mucosal tissue. This is unique in pre-clinical development – likely to lead to fast-tracking through to clinical trials allowing the company to work on ‘proof of concept’.
CSE: PREV SOL-GEL OTCQB: PRVCF PreveCeutical has fingerprinted five cannabis strains. “Sol -gel technology has certainly shown significant promise in laboratory testing at this point. Eventually, I would like to see this proprietary technology be successfully applied to a drug which could be targeted for CNS delivery. At the right time, we would welcome an opportunity to work with a pharmaceutical or biotechnology company to co-develop the Sol-gel and Sol-gel Applicator to be used in pharmaceutical and therapeutic products.” – PreveCeutical’s President & Chief Science Officer, Dr. Mak Jawadekar.
CSE: PREV OTCQB: PRVCF DUAL GENE THERAPY
CSE: PREV DUAL GENE THERAPY OTCQB: PRVCF The American Diabetes Association estimated in 2018 there were more than 500 million prevalent cases of type 2 diabetes worldwide . 1 According to the Institute of Health Metrics and Evaluation, about 30% of the global population is either obese or overweight . 2 • Kills one person every six seconds • 2015 global expenditure $673 Bn USD and 2040 projections $802 Bn USD 3 • Losses in GDP worldwide from 2011-2030 $1.7 Trillion USD 4 1 https://diabetes.diabetesjournals.org/content/67/Supplement_1/202-LB, 2 https://www.grandviewresearch.com/press-release/global-obesity-treatment- market, 3 http://www.diabetesatlas.org/, 4 http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf
CSE: PREV DUAL GENE THERAPY OTCQB: PRVCF PreveCeutical is working with three leading Australian research centres to co-develop a curative therapy for type 2 diabetes and obesity. Our research team has finalized 4 (possibly more) highly potent, and novel Silencing RNA (siRNA) candidates each of which silence the target gene and protein in mice and human-derived cells by more than 80% . The unique sequences of siRNA are PreveCeutical’s IP.
CSE: PREV KEY EXPERTISE OTCQB: PRVCF
CSE: PREV KEY EXPERTISE OTCQB: PRVCF Steven Van Deventer – Chairman and CEO Twenty five years specializing in international corporate relations and business development. Spearheaded the financing and RTO for Aurora Cannabis, now trading on the NYSE, and also helped raise the financing for Hempco. Dr. Mak Jawadekar – President and Chief Science Officer A 28-year Pfizer executive and Director of Portfolio management and part of the team that developed and brought Zoloft to market, one of the worlds most prescribed anti-depressants. Shabira Rajan – Chief Financial Officer and Controller The financial expertise that brought the Canada Line, a $2billion expansion line for the rapid transit systems serving Metro Vancouver, on time and under budget. Dr. Harry Parekh – Chief Research Officer Heads the Drug/Gene Delivery Group at PACE-UQ, the university that brought the world Gardasil, the cervical cancer vaccine. Also holds adjunct positions at the National university of Singapore, and Manipal University India.
CSE: PREV ADVISORY BOARD OTCQB: PRVCF Nicole Goncalves-Krysinski Nicole Goncalves-Krysinski, Esq., is an attorney and a partner in her own law firm in New York City, New York. She has a J.D. from St. John’s University and B.A. from U.C.L.A. Nicole practices in both state and Foreign Legal Advisor federal courts handling a wide range of cases including complex bankruptcy matters, matrimonial and criminal defense litigation. Her areas of practice also include contract negotiations, business and transactional law and corporate advisement. Isaac Moss Isaac Moss B.Sc., M.Pub.Admin. has 30 years of experience in international corporate finance, public markets and business. Isaac was associated with an advisory group in Geneva Switzerland, providing strategic and corporate finance advisory services to a number of client companies around the globe in diverse industries ranging from mining and energy, forest products, technology, telecommunications and bio-technology, and the hospitality industry. Ian has been a serial entrepreneur from his mid 20's having worked in the finance industry working as a commodity broker in central London. Ian studied Business and Finance Law at Brunel University, London, but Ian Spencer chose commercial trading as his passion was for dealing art and antiques which he was extremely successful at. The founder and Director of Concord Business Development, Wanda Halpert is a veteran in the strategic planning industry. She has delivered presentations on the essentials of business planning to public company Wanda Halpert forums and federally funded management programs and directed the productions of over 500 advanced business plans in dozens of industry sectors for both private and public companies.
CSE: PREV SHARE STRUCTURE OTCQB: PRVCF As of June 24 th , 2019. Common shares issued and outstanding: 398,448,905 Updated: 2019-06-04 – 13:14:23 | Symbol: PREV.CN Open: 0.050 Volume: 15000 Last: 0.050 Day Hi: 0.050 Change: 0.00 Day Low: 0.050
Recommend
More recommend